. 2022 Aug;37(8):1101–1111. doi: 10.1177/08850666221086521
© The Author(s) 2022
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
Figure 1.
Compassionate use of inhaled pulmonary vasodilators (IPVD) pathway overview.